MK-3475/BCG in High Risk Superficial Bladder Cancer

NCT02324582 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Intravenous MK-3475/ Intravesical BCG

Sponsor

Southern Illinois University

Collaborators

[object Object]